The metabolic treatment of patients with coronary artery disease: Effects on quality of life and effort Angina

Current Pharmaceutical Design

Volumn 15, Issue 8, 2009, Pages 841-849

  Cesar L A M ^a   Gowdak, L H ^a   Mansur, A P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angina pectoris; Coronary artery disease; Dichloroacetate; L carnitine; Metabolism; Ranolazine; Ribose; Trimetazidine

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIANGINA PECTORIS AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARNITINE; DICHLOROACETIC ACID; DILTIAZEM; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NIFEDIPINE; NITRATE; PLACEBO; PROPRANOLOL; RANOLAZINE; RIBOSE; SILDENAFIL; TRIMETAZIDINE;

ADJUVANT THERAPY; ANGINA PECTORIS; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE INTENSITY; EXERCISE TEST; EXERCISE TOLERANCE; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE FUNCTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; ST SEGMENT; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; STRESS ECHOCARDIOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSPECIFIED SIDE EFFECT;

EID: 65649101870     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787582075     Document Type: Review

References (62)

1. Timmer JR, van der Horst IC, Ottervanger JP. Glucose-insulin-potassium infusion as adjunctive therapy in myocardial infarction: Current evidence and potential mechanisms. Italy Heart J 2004; 5: 727-31.
2. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al. CREATE-ECLA Trial Groupn Ivestigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-46.
3. Lopaschuk GD. Optimising cardiac energy metabolism: A new approach to treating ischaemic heart disease. Eur Heart J Suppl 1999; 1(Suppl): O32-9.
4. Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82: 14K-7K.
5. Gruberg L, Nikolsky E, Beyar R. Stenting in patients with multivessel disease: The new eon? Invasive Cardiol 2002; 14: 6-8.
6. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115(9): 1082-9.
7. Pereira AC, Lopes NH, Soares PR, Krieger JE, de Oliveira SA, Cesar LA, et al. Clinical judgment and treatment options in stable multivessel coronary artery disease results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II). J Am Coll Cardiol 2006; 48: 948-53.
8. Guidelines on the management of stable angina pectoris: Executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-81.
9. Fraker TD Jr, Fihn SD; 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50: 2264-74.
10. 2007 guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536.
11. Thrainsdottir IS, von Bibra H, Malmberg K, Rydén L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004; 44: 101-8.
12. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
13. The degree to which an instrument measures what it is supposed to measure. (Scientific Advisory Committee of the Medical Outcomes Trust; Assessing health status and quality-of-life instruments: Attributes and review criteria. Qual Life Res 2002; 11: 193-205.
14. Campeau L. Grading of angina pectoris [letter]. Circulation 1976; 54: 522-3.
15. The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis, 9th ed. Boston: Little Brown, 1994.
16. Kober G, Buck T, Sievert H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine. Eur Heart J 1992; 13: 1109-15.
17. Prasad R, Singh HK. The efficacy of trimetazidine in stable effort angina. A double blind placebo controlled study. Ind med J 1989; 83: 54-8.
18. Sellier P. Effets de la trimetazidine sur les parametres ergomdtriques dans l'angor d'effort. Etude multicentrique controllée a double insu contre placebo. Arch Mal Coeur 1986; 79: 1331-6.
19. Dalla-Volta S, Maraglino G, Della-Valentina B, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drug Ther 1990; 4: 853- 0.
20. Detry JM, Sellier P, Pennaforte D, Cokkinos D, Dargies H, Mathes P on behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-88.
21. Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K, Szydlowski Z, Paradowski A, et al. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med 2000; 29: 533-8.
22. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: Results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267-74.
23. Manchanda SC. Treatment of stable angina with low dose diltiazem in combination with the metabolic agent trimetazidine. Int J Cardiol 2003; 88: 83-9.
24. Levy S. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 1995; 76: 12B-6.
25. Chazov EI, Lepakchin VK, Zharova EA, Fitilev SB, Levin AM, Rumiantzeva EG, et al. Trimetazidine in Angina Combination Therapy-The TACT Study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12: 35-42.
26. Makolkin VI, Osadchiy KK. Trimetazidine modified release in the treatment of stable angina: TRIUMPH Study TRImetazidine MR in patients with stable angina: Unique metabolic PatH. Clin Drug Investig 2004; 24: 731-8.
27. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 19: CD003614.
28. Danchin N. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina. Am J Cardiol 2006; 98(5A): 8J-13.
29. Szwed H, Sadowski Z, Pachocki R, Domzał-Bocheńska M, Szymczak K, Szydłowski Z, et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther 1999; 13: 217-22.
30. Rodriguez Padial L, Maicas Bellido C, Velázquez Martin M, Gil Polo B. A prospective study on trimetazidine effectiveness and tolerability in diabetic patients in association to the previous treatment of their coronary disease. DIETRIC study. Rev Clin Esp 2005; 205: 57-62.
31. Ribeiro LW, Ribeiro JP, Stein R, Leitão C, Polanczyk CA. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: A randomized crossover trial. Am Heart J 2007; 154: 78.e1-7.
32. Shlyakhto EV, Almazov VV, Nifontov EM, Vakhrameyeva IV, Rudomanov OG, Zakharov DV, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002; 2: 119-24.
33. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
34. Mathias W Jr, Tsutsui JM, Andrade JL, Kowatsch I, Lemos PA, Leal SM, et al. Value of rapid beta-blocker injection at peak dobutamine-atropine stress echocardiography for detection of coronary artery disease. J Am Coll Cardiol 2003; 41: 1583-89.
35. Cesar LA, Mathias W Jr, Armaganijan D, Gimenez V, Jallad S, Del Monaco MI, et al. Trimetazidine to reverse ischemia in patients with class I or II angina: A randomized, double-blind, placebo-controlled dobutamine-atropine stress echocardiography study. Coron Artery Dis 2007; 18: 259-63.
36. Ruzyllo W, Szwed H, Sadowski Z, Elikowski W, Grzelak-Szafranska H, Orszulak W, et al. Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004; 20: 1447-54.
37. Kl̈bel F, Bada V. Trimetazidine in geriatric patients with stable angina pectoris: The tiger study. Int J Clin Pract 2003; 57: 867-70.
38. Ware Jr, JE, Sherbourne, CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
39. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
40. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, et al. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease. J Am Coll Cardiol 1995; 25: 333-41.
41. Vitale C, Wajngarten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25: 1814-21.
42. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New Engl J Med 1982; 306: 1081-8.
43. Rosano GM, Marazzi G, Patrizi R, Cerquetani E, Vitale C, Volterrani M, et al. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease. Am J Cardiol 2005; 95: 327-31
44. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93: 135-42.
45. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-10.
46. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: Effects of the late sodium current inhibitor ranolazine. Heart 2006; 92(Suppl 4): Iv6-iv14.
47. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375-82.
48. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004; 291: 309-16.
49. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48: 566-75.
50. Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002; 27: 621-36.
51. Arsenian MA. Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 1997; 40: 265-86.
52. Cherchi A, Lai C, Angelino F, Trucco G, Caponnetto S, Mereto PE, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985; 23: 569-72
53. Iyer RN, Khan AA, Gupta A, Vajifdar BU, Lokhandwala YY. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India 2000; 48: 1050-2.
54. Pauly DF, Pepine CJ. D-Ribose as a supplement for cardiac energy metabolism. J Cardiovasc Pharmacol Ther 2000; 5: 249-58.
55. Zimmer HG, Ibel H. Ribose accelerates the repletion of the ATP pool during recovery from reversible ischemia of the rat myocardium. J Mol Cell Cardiol 1984; 16: 863-6.
56. Pliml W, von Arnim T, Stäblein A, Hofmann H, Zimmer HG, Erdmann E. Effects of ribose on exercise-induced ischaemia in stable coronary artery disease. Lancet 1992; 340: 507-10.
57. Omran H, Illien S, MacCarter D, St Cyr J, Lüderitz B. D-Ribose improves diastolic function and quality of life in congestive heart failure patients: A prospective feasibility study. Eur J Heart Fail 2003; 5: 615-9.
58. Sakai K, Ichihara K, Nasa Y, Kamigaki M, Abiko Y. Dichloroacetate attenuates myocardial acidosis and metabolic changes induced by partial occlusion of the coronary artery in dogs. Arch Int Pharmacodyn Ther 1990; 307: 92-108.
59. Wargovich TJ, MacDonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am J Cardiol 1988; 61: 65-70.
60. Barantke M, Bonnemeier H. Factor Xa inactivation in acute coronary syndrome. Curr Pharm Des 2008; 14(12): 1186-90.
61. Huston SA, Hawkins D. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention. Curr Pharm Des 2008; 14(12): 1197-204.
62. Neglia D, Rimoldi O, Kaufmann PA, Camici PG. Radionuclide PET and PET/CT in coronary artery disease. Curr Pharm Des 2008; 14(18): 1798-814.